The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLLS | +154.17% | -86.19% | -32.69% | -89% |
| S&P | +19.32% | +83.47% | +12.91% | +239% |
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
The company bucked the recent downward trend for biotech companies.
Investors saw a bargain when the stock hit its 52-week low early in the week.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $35.02M | 115.5% |
| Gross Profit | $30.03M | 160.8% |
| Gross Margin | 85.76% | 14.9% |
| Market Cap | $205.47M | 34.4% |
| Market Cap / Employee | $925.53K | 0.0% |
| Employees | 222 | 0.0% |
| Net Income | $586.38K | 102.5% |
| EBITDA | $10.86M | 234.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.29M | -65.9% |
| Accounts Receivable | $8.06M | -27.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $92.65M | -5.7% |
| Short Term Debt | $26.57M | 91.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -9.67% | 25.0% |
| Return On Invested Capital | -36.66% | 2.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,809.79K | 59.0% |
| Operating Free Cash Flow | -$1,626.67K | 73.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.39 | 0.95 | 1.32 | 2.94 | 79.57% |
| Price to Sales | 7.29 | 2.61 | 2.71 | 3.85 | -73.22% |
| Price to Tangible Book Value | 1.40 | 0.96 | 1.32 | 2.98 | 80.76% |
| Price to Free Cash Flow TTM | 3.81 | 3.55 | 4.85 | - | |
| Enterprise Value to EBITDA | -8.80 | 0.97 | -10.57 | 19.98 | -758.90% |
| Free Cash Flow Yield | 26.2% | 28.1% | 20.6% | - | |
| Return on Equity | -34.2% | -58.6% | -48.4% | -31.1% | -69.56% |
| Total Debt | $109.65M | $108.82M | $113.83M | $119.22M | 6.34% |
No podcast episodes available.
CLLS earnings call for the period ending September 30, 2021.
CLLS earnings call for the period ending August 6, 2021.
CLLS earnings call for the period ending December 31, 2020.
CLLS earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
